The 68th(2026)China National Pharmaceutical Machinery Exposition recently concluded at the Xiamen International Expo Center.Aquacells presented its independently developed electrodeionization(EDI)equipment for purified water production,designed for hot-water sanitization.Advances in proprietary membrane materials offer pharmaceutical water treatment equipment manufacturers a domestically developed option with greater control over core technology and supply.

Addressing Industry Challenges

EDI technology capable of reliably withstanding pasteurization with hot water at 85°C has long been dominated by overseas suppliers.Most EDI products manufactured in China have struggled to accommodate these sanitization conditions,leaving Chinese pharmaceutical companies reliant on imported products and exposed to high procurement costs and supply chain risks.

To address this technology gap,Aquacells has continued to invest in membrane materials research.Following multiple rounds of high-temperature durability testing,the company developed a domestically produced EDI module compatible with hot-water sanitization.The module supports the pharmaceutical industry's requirement for pasteurization with hot water at 85°C,helping to control microbial growth in the system.It maintains stable product water quality after hundreds of sanitization cycles,meeting stringent requirements for pharmaceutical water.

Exhibition Highlights

At the exhibition,Shandong Eagle Pharma Machinery Co.,Ltd.(WEMAC)displayed a complete pharmaceutical purified water system incorporating Aquacells'hot-water-sanitizable EDI module in the same hall as the Aquacells booth.The displays attracted visitors for technical discussions.Equipment manufacturers and representatives of pharmaceutical companies expressed interest in cooperation after reviewing product performance,operating data and application cases.

The module has already been adopted by several leading pharmaceutical equipment manufacturers,with total shipments exceeding 100 units.Customer operating data show stable water quality and reliable performance during high-temperature sanitization.Market acceptance continues to grow,and several overseas pharmaceutical projects incorporating the module are progressing toward implementation.

Aquacells'products are built on its proprietary,patented membrane technology and are supported by international certification and compliance credentials relating to FDA and EU requirements,CE,RoHS and REACH.These strengths have also attracted purchasing interest from overseas customers,helping Aquacells expand its presence in the global pharmaceutical purified water market with reliable technology developed in China.

Serving High End Industries Worldwide

Developing domestic alternatives requires capabilities in materials,manufacturing processes and service that go beyond matching technical specifications.Through continued improvements to its products,solutions and services,Aquacells is establishing a repeatable,scalable approach to replacing imported products,helping meet demand for purified water in pharmaceutical water treatment worldwide.

With the exhibition concluded,Aquacells will continue its research and development in membrane materials for ultrapure water.Working with industry partners,the company will advance its products through technological innovation and support end users'production with reliable quality.It aims to provide high-end industries worldwide with solutions developed in China that offer higher standards,smarter operation and greater stability.